To validate the methodology of isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques and to gain insight into the distribution of tumor necrosis factor-alpha (TNF), melphalan, and mitomycin C (MMC) through the regional and systemic blood compartments when applying these techniques.
Objective
To validate the methodology of isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques and to gain insight into the distribution of tumor necrosis factor-alpha (TNF), melphalan, and mitomycin C (MMC) through the regional and systemic blood compartments when applying these techniques.
Summary Background Data
There is no standard treatment for unresectable liver tumors. Clinical results of isolated limb perfusion with high-dose TNF and melphalan for the treatment of melanoma and sarcoma have been promising, and aftempts have been made to extrapolate this success to the isolated liver perfusion setting. The magnitude and toxicity of the surgical procedure, however, have limited clinical applicability.
Methods
Pigs underwent IHHP with TNF, melphalan, and MMC using balloon catheters or served as controls, receiving equivalent dosages of these agents intravenously. After a 20-minute perfusion, a washout procedure was performed for 10 minutes, after which isolation was terminated. Throughout the procedure and afterward, blood samples were obtained from the hepatic and systemic blood compartments and concentrations of perfused agents were determined.
Results
During perfusion, locoregional plasma drug concentrations were 20-to 40-fold higher than systemic concentrations. Compared with systemic concentrations after intravenous administration, regional concentrations during IHHP were up to 1 0-fold higher. Regional MMC and melphalan levels steadily declined during perfusion, indicating rapid uptake by the liver tissue; minimal systemic concentrations indicated virtually no leakage to the systemic blood compartment. During isolation, concentrations of TNF in the perfusate declined only slightly, indicating limited uptake by the liver tissue; no leakage of TNF to the systemic circulation was observed. After termination of isolation, systemic TNF levels showed only a minor transient elevation, indicating that the washout procedure at the end of the perfusions was fully effective.
Conclusions
Complete isolation of the hepatic vascular bed can be accomplished when performing IHHP using this balloon catheter technique. Thus, as in extremities, an ideal leakage-free perfusion of the liver can now be performed, and repeated, without major surgery. The effective washout allows the addition of TNF in this setting. The main principle of isolated regional chemotherapy is to achieve higher regional drug concentrations and thus higher exposure of tumor tissue to the agents, resulting in increased response rates, while shielding the organism from the systemic toxicity because of the much lower concentrations in the systemic circulation. These principles are even more important for the potential application of tumor necrosis factor-alpha (TNF). The toxicity of this cytokine has made systemic application of adequate doses with antitumor effect impossible.'0'11 However, in a leakage-free isolated perfusion setting, it can be safely used with remarkable results. Response rates of >80% have been observed in the treatment of unresectable extremity soft-tissue sarcomas using isolated limb perfusion with TNF plus melphalan.12 '13 In the wake of these promising clinical results, efforts have been made to translate this success to other regional perfusion settings. The liver is one of the most obvious targets, and successful isolated perfusions of the liver with cytostatic drugs, both in animal models and in humans, have been reported. 14-16 The applicability of TNF in the setting of leakage-free isolated liver perfusion has been reported by teams from the National Cancer Institute and by us. [17] [18] [19] Major drawbacks of clinical application, however, are the magnitude and associated toxicity of the surgical procedure and the complexity and costs of using a venous bypass system as well as a heart-lung machine 
Perfusion Set
Perfusion sets were kindly provided by PfM GmbH (Cologne, Germany) and consisted of a double-balloon catheter (12F, balloon capacity 25 ml, distance between balloons 4 cm) for venous isolation of the liver, an aortic occlusion balloon catheter (12F, balloon capacity 25 ml) for compensating the decrease in cardiac preload during the procedure, and a tubing set with a volume of 220 ml containing a bubble trap. In the perfusion circuit, flow was maintained by a roller pump, and the temperature of the perfusate was regulated by a heat exchanger (Cardioplegia heat exchanger, CSC14 Sorin, Biomedica, Italy). Drugs were infused through a sideline into the perfusion circuit.
Surgical Procedure Figure 1 illustrates the methodology of an isolated hypoxic hepatic perfusion (IHHP) with balloon catheters. It shows the position of the occlusion catheters, the inflow catheter in the gastroduodenal artery, and the other components of the perfusion circuit. The IHHP procedure was carried out as follows. General anesthesia was induced in pigs by standard methods and maintained with pancuronium and fentanyl. An arterial line was introduced into a carotid artery and a double-lumen central venous catheter was placed in an external jugular vein on either side. After a midline laparotomy was performed, the gastroduodenal or common hepatic artery was cannulated with the arterial infusion catheter (7F). Pigs were subsequently heparinized with 2 mg/kg heparin. After formal surgical exposure of the femoral vessels, the aortic occlusion catheter was introduced into the common femoral artery. Subsequently the double-balloon catheter was introduced into the common femoral vein and retrogradely moved up into the caval vein, positioning the balloons above and below the hepatic veins. To compensate for the decrease in cardiac preload, the aorta was clamped or the aortic occlusion balloon was inflated. Caval balloons were then inflated and temporary isolation of the hepatic vascular bed was obtained by clamping the hepatic artery and subsequently the portal vein. After connecting the double-balloon catheter and arterial cannula to the perfusion system primed with 220 ml Haemaccel (Behring Pharma, Amsterdam, The Netherlands), the perfusate was circulated by means of a roller pump with a constant flow of 200 ml/minute. plates were incubated with a polyclonal rabbit antihuman TNF antiserum, followed by addition of an enzyme-labeled antirabbit reagent and enzyme reaction. The detection limit for human TNF was 20 pg/ml.
Melphalan in plasma was measured by gas chromatography/mass spectrometry. P-[Bis(2-chloroethyl)amino]-phenylacetic acid methyl ester was used as an internal standard. Samples were extracted over trifunctional C18 silica columns. After elution with methanol and evaporation, the compounds were derivatized with trifluoroacetic anhydride and diazomethane in ether. The stable derivatives were separated on a methyl phenyl siloxane GC capillary column and measured selectively by single ion monitoring mass spectrometry in the positive El mode. The detection limit for melphalan is 10 pg/ml. Details of this assay were described by us. 32 Concentrations of MMC were analyzed by high-performance liquid chromatography with ultraviolet detection. Porfiromycin was used as an internal standard. Samples were extracted over XAD-2 columns. After elution with methanol and evaporation, the dry residue was diluted in the mobile phase, which consisted of methanol and water (40/60 Figure 2 shows the mean systemic plasma concentrations of MMC, melphalan, and TNF after administration of these agents as an intravenous bolus. A typical one-phase exponential decay curve was observed for TNF and MMC with an elimination half-life of 31 minutes for TNF and 7.2 minutes for MMC. Two-phase exponential decay was ob- served for melphalan with a Al of 2.8 and a A2 of 161 minutes. During perfusion, concentrations of MMC and melphalan were markedly greater in the isolated hepatic vascular compartment than in the systemic compartment (Fig. 3) . After 5 minutes of perfusion, mean MMC peak levels were 38-fold higher than systemic peak MMC plasma concentrations (2222 ng/ml vs. 59 ng/ml). Mean melphalan peak levels at 5 minutes were 33-fold higher than mean systemic plasma concentrations (3028 ng/ml vs. 93 ng/ml). During the 20 minutes of perfusion, MMC and melphalan plasma levels in the isolated hepatic vascular compartment steadily declined. However, systemic levels of melphalan and MMC remained at <93 ng/ml and 59 ng/ml, respectively, throughout the procedure, indicating no significant leakage from the isolated circuit. The mean plasma concentration of TNF at 5 minutes was 840 ng/ml; it remained virtually stable throughout perfusion, not exhibiting the regional concentration decline observed for MMC and melphalan (Fig. 4) . Systemic TNF concentrations remained at <22 ng/ml throughout the 20 minutes of perfusion. As a result of the washout procedure, regional TNF concentrations declined from 648 ng/ml to 99 ng/ml. Five minutes after termination of isolation, systemic TNF levels showed only a small rise to 50 ng/ml. 500-to perfused drugs was 20 to 40 times greater than systemic exposure. Because of the leakage-free quality of the method, these ratios are just as good as those observed with classic surgical isolated liver perfusions.'7"8'34 Regional MMC and melphalan levels declined rapidly during perfusion, indicating a fast uptake by the liver tissue; concomitant minimal systemic concentrations indicated virtually no leakage to the systemic blood compartment. This holds true not only for the parent drugs, but also for possible toxic metabolites and degradation products.32 During isolation, concentrations of TNF in the perfusate declined only slightly, indicating limited uptake by the liver tissue; no leakage of TNF was observed. After termination of isolation, systemic TNF levels showed only a minor transient elevation, indicating that the washout procedure at the end of the perfusion was fully effective.
Areas Under the Curve
One could argue that regional/intravenous AUC ratios (see Table 1 19 In conclusion, we have demonstrated that IHHP has favorable pharmacokinetic characteristics for both TNF and cytostatic agents that equal those that can be achieved by the major procedure of a classic surgical isolated liver perfusion. Moreover, the balloon catheter procedure can be repeated, which is of eminent importance in prolonging control of metastatic disease in the liver. IHHP may provide a new chance to reintroduce TNF into the clinical setting in an attempt to translate its success in combination with chemotherapy in isolated limb perfusions into the treatment of the much more common problem of managing unresectable malignant disease to the liver.
